Drug Trial Radar · NCT04064359
Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jul 25, 2019
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Oxford BioTherapeutics LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 21, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an "Investigational Drug", which means that it is still being studied and has not yet been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authorities to be prescribed by doctors for the treatment of metastatic or recurrent solid tumors. The use of OBT076 in this study is investigational. This is a Phase I research study designed to look at several dose levels of the study drug to find the highest dose level that is safe and well-tolerated (does not cause unacceptable side effects), and to examine the effects of the study drug in a small group of research participants. The study will also look at the effectiveness of OBT076 as an anti-cancer therapy. Once the optimal dose is determined and safety is assessed, additional research participants will be treated at the optimal dose level to further evaluate safety and effectiveness.
Conditions
- Solid Tumor
Interventions
OBT076, a CD205-directed antibody-drug conjugateDrug
Intravenous (IV) infusion of OBT076 every 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs) as assessed by NCI CTCAE (Version 5)Time frame: 1 year
- Percentage of subjects with dose-limiting toxicities (DLTs) as assessed by NCI CTCAE (Version 5)Time frame: 1 year
Locations
27 sites in 5 countries. Site status is shown where the registry gives one.
Mayo Clinic
Phoenix, Arizona
Cedars-Sinai
Los Angeles, California
UCLA
Santa Monica, California
Moffitt Cancer Center
Tampa, Florida
The State University of Iowa
Iowa City, Iowa
St. Elizabeth Healthcare
Edgewood, Kentucky
University of Mississippi Medical Center
Jackson, Mississippi
Quantum Santa Fe
Santa Fe, New Mexico
Columbia University Medical Center
New York, New York
University of Pittsburgh
Pittsburgh, Pennsylvania
Institut Jules Bordet
Brussels, Belgium
AZ Groeninge
Kortrijk, Belgium
Institut Paoli Calmettes
Marseille, France
GHP Saint-Joseph
Paris, France
Hopital Saint Antoine
Paris, France
Hopital Saint Louis
Paris, France
Centre Eugène Marquis
Rennes, France
ICANS - Institut de cancérologie Strasbourg
Strasbourg, France
Institut Gustave Roussy - IGR
Villejuif, France
Metropolitan Hospital
Athens, Greece
Sotiria General Hospital
Athens, Greece
University General Hospital of Heraklion
Heraklion, Greece
EuroMedica
Thessaloniki, Greece
University General Hospital Attikon
Chaïdári, Athens, Greece
START Barcelona HM Nou Delfos
Barcelona, Spain
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
University Hospital Marqués de Valdecilla
Santander, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.